Please find the recording of the BioPub.co video conference held June 1, 2020 entitled Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD.
About Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF)
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
BioPub is an online subscription service reviewing small-cap biotech companies. It is led by an NIH-trained MD, PhD former medical professor and researcher, and his colleagues. The BioPub team works to identify exceptional companies, representing what it regards as the top decile of biotech investing opportunities on the basis of three concurrent attributes: genuine top-shelf science; credible, competent, and accessible management; and the likelihood that a company’s efforts will permanently alter the landscape of clinical medicine. For more information, visit the company’s website at www.biopub.co